West Pharma Lifts FY EPS Outlook to $9.38-$9.48 After Q3 Beat
WST sits 84% above its 52-week low of $223.83.
Summary
West Pharmaceutical raised full-year adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05 and revenue to $3.41-$3.42 billion from $3.345-$3.380 billion. The raise follows a strong third quarter: net income jumped to $214.0 million, or $3.02 per share, from $140.0 million, or $1.92 per share, a year earlier, on revenue of $874.5 million, up 8.7%. Adjusted EPS came in at $2.66. Shares rose nearly 2% in premarket trading after closing at $403.64 Wednesday, and the stock is already trading near its 52-week high. The guidance raise follows the 8-K filed this morning confirming the Q3 beat and the new $950 million credit agreement signed October 26th.
At the time of this announcement, WST was trading at $410.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $28.4B. The 52-week trading range was $223.83 to $404.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.